DrugPatentWatch Database Preview
Lannett Co Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for LANNETT CO INC, and when can generic versions of LANNETT CO INC drugs launch?
LANNETT CO INC has one hundred and thirty-three approved drugs.
There is one US patent protecting LANNETT CO INC drugs. There is one tentative approval on LANNETT CO INC drugs.
There are fifteen patent family members on LANNETT CO INC drugs in twelve countries and one hundred and sixteen supplementary protection certificates in twelve countries.
Summary for Lannett Co Inc
| International Patents: | 15 |
| US Patents: | 1 |
| Tradenames: | 102 |
| Ingredients: | 95 |
| NDAs: | 133 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for Lannett Co Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett Co Inc | CODEPREX | chlorpheniramine polistirex; codeine polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 021369-001 | Jun 21, 2004 | DISCN | No | No | Start Trial | Start Trial | |||||
| Lannett Co Inc | HYDROCHLOROTHIAZIDE | hydrochlorothiazide | CAPSULE;ORAL | 091662-001 | Jan 27, 2012 | DISCN | No | No | Start Trial | Start Trial | |||||
| Lannett Co Inc | DOXYCYCLINE | doxycycline | TABLET;ORAL | 065285-001 | Dec 8, 2005 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lannett Co Inc | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 091624-003 | Apr 5, 2013 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lannett Co Inc | BUTALBITAL, ACETAMINOPHEN AND CAFFEINE | acetaminophen; butalbital; caffeine | CAPSULE;ORAL | 212083-001 | Dec 17, 2019 | AA | RX | No | No | Start Trial | Start Trial | ||||
| Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-005 | Feb 19, 2006 | AB2 | RX | Yes | No | Start Trial | Start Trial | ||||
| Lannett Co Inc | METHYLPHENIDATE HYDROCHLORIDE | methylphenidate hydrochloride | TABLET;ORAL | 086428-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lannett Co Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lannett Co Inc | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT CO INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 10 mg, 20 mg and 30 mg | ➤ Subscribe | 2005-05-13 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-03-15 |
International Patents for Lannett Co Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 203828 | Start Trial |
| European Patent Office | 2286815 | Start Trial |
| Cyprus | 1118946 | Start Trial |
| Hungary | 0303695 | Start Trial |
| European Patent Office | 2103307 | Start Trial |
| European Patent Office | 1328251 | Start Trial |
| Japan | 2004512296 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lannett Co Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1429780 | SPC/GB12/058 | United Kingdom | Start Trial | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 0513917 | SPC/GB98/019 | United Kingdom | Start Trial | PRODUCT NAME: A COMBINATION COMPRISING LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND ZIDOVUDINE; REGISTERED: UK EU/1/98/058/001 19980318; UK EU/1/98/058/002 19980318 |
| 0392059 | SPC/GB02/046 | United Kingdom | Start Trial | PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515 |
| 0162036 | C300028 | Netherlands | Start Trial | PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929 |
| 0166287 | SPC/GB96/056 | United Kingdom | Start Trial | PRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604 |
| 0347066 | 10399030 | Germany | Start Trial | PRODUCT NAME: ESCITALOPRAMOXALAT; NAT. REGISTRATION NO/DATE: 55880.00.00 55880.01.00 55880.02.00 55880.03.00 55884.00.00 55884.01.00 55884.02.00 55884.03.00 55888.00.00 55888.01.00 55888.02.00 55888.03.00 20030408 FIRST REGISTRATION: SCHWEDEN 17084 17085 17086 17087 20011207 |
| 0296749 | SPC/GB96/004 | United Kingdom | Start Trial | PRODUCT NAME: ANASTROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT; REGISTRATION NO/DATE: UK 12619/0106 19950811 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
